Plain-English translation of NCT05286814 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called combined with two existing treatments: a special chemotherapy pump surgically placed to deliver medicine directly to the liver, and standard systemic chemotherapy (drugs given intravenously). The study aims to see if this combination helps shrink tumors in people with advanced cancers that have spread to the liver.
Current liver-targeted chemotherapy hasn't improved much in decades, and patients often need dose reductions that limit how well the treatment works. Researchers believe this medication might work better by waking up the immune system to attack tumors right where the chemotherapy has already damaged them, creating a more powerful effect against cancer.
You likely qualify if…
You likely don't qualify if…
You would undergo surgery to have a chemotherapy pump placed in an artery that feeds your liver. Once healed, you would receive the new medication through injections, followed by the chemotherapy pump delivering medicine directly to your liver, and then standard intravenous chemotherapy. You would need multiple visits for treatment, imaging, and blood tests over several months. Your medical team would monitor you closely for side effects and how well the treatment is working.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States